Introduction:
Globally, it is estimated that more than 33.3 million people are living with human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) in 2009, over 50% were women , transmission of HIV (MTCT) from mother to child accounts for about 90% of HIV infection in new born and young kids. Over 370,000 infants acquire HIV infections globally each year with roughly more than 1000 children acquiring HIV each day (1) .
HIV-infected infants and young children have high risk of mortality because of rapid advancement of disease (2) .
It is projected that up to 30% of untreated HIV-infected children die before one year and more than 50% die before the age of 2 years (3) , there is urgent need to identify and enroll them into care and treatment programs.
Early Infant Diagnosis (EID) of HIV finds early HIV status and management to comprehensive AIDS care and treatment of infected infants. EID of HIV is carried out by detection of infant blood RNA or DNA. In places where resources are limited, for EID venous blood has been used to carry out DNA polymerase chain reaction (PCR) test of HIV in children less than 1.5 years. Numerous studies have reported the transfer from venous blood to dried blood spot (DBS) specimen .
HIV-specific antibody detection is the most commonly used approach for the diagnosis of HIV infection.
However, antibodies usually appear about 3-4 weeks after initial HIV infection .Several types of assays for HIV antibody detection have been developed and promoted for HIV screening and diagnosis (4) . Enzymelinked immunosorbent assay (ELISA) is the most commonly used technique for screening purposes in developed countries, followed by confirmatory testing most commonly by using conventional Western blot (WB). There are many different commercially available ELISAs for detection of antibodies to HIV. In 1985, first-generation indirect ELISAs employed whole virus antigens obtained from cell cultures which were bound to the solid phase on the bottom of the wells of microtitre plate . The first generation ELISAs were sensitive but less specific with capacity to detect early HIV antibodies slightly more than 40 days after infection (5) . The secondgeneration ELISAs used an indirect format, HIV recombinant antigens and 28 peptides bound in solid phase . The assays had increased specificity and good sensitivity that reduced the window period to detect antibodies as early as 33-35 days after infection (6) . In 1990s, due to diverse HIV variability, ELISAs were introduced which also included antigens from HIV-2 and new antigens from viruses of the HIV-1 groups M, N and O
. Blood samples from HIV infected subjects and blood samples from healthy volunteers were collected from outpatients from a local hospital in Secunderabad.
2.
Roche RNA extraction kit(for extraction of RNA from HIV infected plasma),
3.
Genosens HIV-1 RT-PCR kit( for reverse transcription of HIV RNA and real time PCR for implication of HIV LTR gene)
4.
Tridot Rapid kit( for screening HIV1 and HIV 2 antibodies) 
Study Design
• 20 HIV positive serum /blood samples were collected from a local hospital in
Secunderabad
• 20 Blood samples were collected from healthy controls who were not having HIV infection.
• Rapid tridot tests were done on all the 40 samples
• The fourth generation CIA test was done on all 40 samples using ARCHITECT.
The 20 HIV positive samples were further subjected to a confirmatory test by RT-PCR
Results:
The samples collected from both male and female individuals ranging between the age of 20 to 43 years from local hospital, Secundrabad. Out of the total 20 patient samples tested for HIV-1 and /or HIV-2 infection,18 proved to be seropositive for HIV-1 with no case of HIV detected using Tridot method, but using CIA and RT-PCR method all 20 proved to be HIV positive.
In AG-AB combo assay of ARCHITECT, the assay result is presented as ratios of specimen signals to the cut-off values (S/CO), where an S/CO ratio ≥ 1.00 is considered reactive. Though these assays have been shown to reduce the HIV window period by 4-5 days compared with 3 rd generation HIVAb detection assays. Discrepant results have been published on their specificities in population groups with low HIV prevalence. Some chronic infections may cause false positive HIV results. The only findings that related to the false positivity of the HIV test result could be that the patient was suffering from chronic HBV infection. There are reports of false positive result after HBV vaccination or treatment with hepatitis B immune globulin; therefore it may be assumed that false positivity may be due to chronic HBV infection.
It is suggested that, laboratories in low prevalent countries like Nepal, Bangladesh, srilanka, etc. using 4 th generation CMIA should interpret their result cautiously. In addition, this types of discrepant result reemphasis the need of confirming HIV positive test result by WB or LIA. Rapid testing systems allow the HIV assays to be run in 5 to 20 minutes. Negative rapid test assays can be considered negative unless there concern of acute HIV infection; however, all positive rapid assays must be confirmed by standard ELISA and Western Blot assays. Currently available U.S.
Food and Drug Administration (FDA)-approved kits are available for blood, plasma, serum, and saliva specimens. These tests are particularly beneficial in the delivery room, emergency room, and after occupational exposures. Additionally, the availability of Clinical Laboratories Improvement Act-waived testing allows these assays to be run in the community, expanding access to testing.
Home tests are available that allow patients to collect a blood sample after a finger stick, which is Early detection of infection is vital for patient management and the prevention of HIV transmission. The fourth-generation assays can detect HIV nearly 6 days before the thirdgeneration assays and sometimes before p24 antigen-only assays, and less than 3 days after nucleic acid tests.
In a previous report by Kwon et al., the ARCHITECT combo assay detected infection 4-26 days earlier than third-generation assays.
The Elecsys HIV combi PT assay has been standard-ized to the WHO reference standard for p24
antigen and has an overall analytical sensitivity of 1.05 IU/mL at a cut-off index of 1.0.
Previous studies investigating laboratory-based (as opposed to point-of-care based) HIV assays have documented that HIV-1 O strains and HIV-1 subtypes F and C have not been detected by some assays, and the difficulty in diagnosing HIV-1 group O has also been highlighted by the case http://arab.kmshare.net/ 3111 described by Henquell et al. Genetic variability, particularly of gp41, may affect the ability of enzyme assays to detect HIV antibodies (13) .
Real time PCR-Viral load testing should be performed at a patient's initiation of HIV care. Viral load testing targets any one gene of HIV genome . the most commonly used region is the LTR region . Subsequent viral load testing is used as a marker for HIV viremia and should be tested every three to six months among those on treatment. New guidelines also recommend viral load testing two to eight weeks after the initiation of HAART to determine early response to therapy. Viral load can also be used to determine non-adherence or treatment failure as defined by a viral load of >200 copies/mL.
Thus, drawbacks to currently available rapid tests include a lower sensitivity than third-and fourthgeneration EIA tests and, RT-PCR depending on the prevalence of infection in the population being tested, a low (< 90%) positive predictive value. RT-PCR has better positive pridictive value and in comparison to rapid tests and 3rd And 4 th generation ELISA assays.
Conclusion
To summarize, our study shows that chemiluminescence based ELISA is 100 % sensitive and is comparable to RT-PCR method. In our view, Rapid tests can often give false positives or false negatives.
Each test has its own drawbacks. In some instances even the viral load tests give false results, the limitation of this study has been the small sample size. 
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